Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a Phase 1b study on combination chemo-immunotherapy for metastatic endocrine-resistant breast cancer, while adding a new study identifier and a revision number. The core content regarding the study's methodology and patient eligibility criteria has been largely deleted.SummaryDifference54%
- Check20 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check78 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
- Check85 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.